Benjamin Dizier

Predictive Gene Signature in MAGE-A3 Antigen-Specific Cancer Immunotherapy

Fernando Ulloa‐Montoya, Jamila Louahed, Benjamin Dizier et al. · Journal of Clinical Oncology · 2013 · 461 citations · Full text

Pretreatment Expression, Immunology, Immunoediting +20

MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial

Brigitte Dréno, John F Thompson, B. Mark Smithers et al. · The Lancet Oncology · 2018 · 190 citations

Tumor Immunology, Cancer Immunosurveillance, Medicine +11

A Predictive Enrichment Procedure to Identify Potential Responders to a New Therapy for Randomized, Comparative Controlled Clinical Studies

Junlong Li, Lihui Zhao, Lü Tian et al. · Biometrics · 2015 · 47 citations · Full text

Engineering, Patient Selection, Clinical Endpoint +18

Bimekizumab for the treatment of moderate‐to‐severe plaque psoriasis: efficacy, safety, pharmacokinetics, pharmacodynamics and transcriptomics from a phase IIa, randomized, double‐blind multicentre study*

Ruth Oliver, James G. Krueger, Sophie Glatt et al. · British Journal of Dermatology · 2021 · 45 citations · Full text

A Th1/IFNγ Gene Signature Is Prognostic in the Adjuvant Setting of Resectable High-Risk Melanoma but Not in Non–Small Cell Lung Cancer

Benjamin Dizier, Andrea Callegaro, Muriel Debois et al. · Clinical Cancer Research · 2019 · 16 citations · Full text